İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2025

Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study

Journal of Clinical Medicine

YÖKSİS OpenAlex Açık erişim · gold SJR Q2 JCR Q1 Atıf 0 Yüzdelik 14.7% FWCI 0.0
Yıl
2025
ISSN
2077-0383
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Background/Objectives: In this retrospective study, we aimed to compare the efficacy, survival, and toxicity results of induction (IC) or adjuvant (AC) treatment with chemoradiotherapy (CRT) in locally advanced nasopharyngeal cancer (NPC). Methods: A total of 405 patients from 22 different centres in Turkey, belonging to the Turkish Oncology Group (TOG), was included. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoints were safety and toxicity. Results: The median age of the patients included in the study was 49 (18.2–91.5) years. In total, 298 (73.6%) of the patients were male. Of the 405 patients, 258 (63.7%) received IC and 147 (36.3%) received AC treatment. When OS and PFS analyses were performed in terms of age, gender, T and N stages, pathological features, and treatments received, no effect of any variable on prognosis was observed. For the overall group, the median estimated OS was 137.3 months (the Kaplan–Meier statistical method could not reach the 95% confidence interval [CI]). For the IC group, the median estimated survival was 137.3 months (95% CI: 111.4–163.3), whereas the Kaplan–Meier statistical method could not estimate survival for the AC group. No statistically significant difference was observed between IC and AC groups in terms of OS (p = 0.209) or PFS (p = 0.248). Grade 3–4 side effects were observed in 12% of patients in the IC group and 29.9% of patients in the AC group. Treatment was discontinued due to toxicity in 5 patients (1.9%) in the IC group and 18 patients (12.2%) in the AC group. Conclusion: No difference in OS or PFS was observed between AC and IC treatments. More grade 3–4 side effects were observed in the AC-treated group and early discontinuation rate was higher.

Konular

  • Head and Neck Cancer Studies
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies

Birincil konu Head and Neck Cancer Studies

Yazarlar

  1. SERHAT SEKMEK
  2. AYSEL OĞUZ
  3. MELEK KARAKURT ERYILMAZ NECMETTİN ERBAKAN ÜNİVERSİTESİ
  4. MURAT ARAZ NECMETTİN ERBAKAN ÜNİVERSİTESİ
  5. SEDAT BİTER
  6. MEHMET MUTLU KIDI
  7. ERTUĞRUL BAYRAM
  8. EFE CEM ERDAT
  9. HATİME ARZU YAŞAR
  10. RUMEYSA ÇOLAK
  11. MESUT YILMAZ
  12. GİZEM BAKIR KAHVECİ
  13. DİDEM DİVRİKLİOĞLU
  14. ELVIN CHALABIYEV
  15. SERCAN AKSOY
  16. SEMA NUR ÖZSAN ÇELEBİ
  17. HAKAN KOSKU
  18. İLHAN HACIBEKİROĞLU
  19. HAYDAR TEMİZYÜREK
  20. KÜBRA CANASLAN
  21. GÖRKEM TURHAN
  22. AHMET KADIOĞLU
  23. SEDA JERAL
  24. MEHMETCAN ATAK
  25. HÜSEYİN ATACAN
  26. ANIL ÖZBAY
  27. TUGAY ATASEVER
  28. MUSTAFA SEYYAR
  29. PERVİN CAN ŞANCI
  30. BAHADIR KÖYLÜ
  31. NARGIZ MAJIDOVA
  32. ERKAN ARPACI
  33. MUHAMMED BÜLENT AKINCI
  34. DOĞAN UNCU
  35. GÖKHAN UÇAR